Although low risk localised prostate cancer has an excellent prognosis owing to effective
treatments, such as surgery, radiation, cryosurgery and hormone therapy, metastatic …

Background Castration-resistant prostate cancer (CRPC) occurs when prostate cancer
(CaP) progresses under therapy-induced castrate conditions. Several mechanisms have …

Neuroendocrine prostate cancer (NEPC) encompasses various clinical contexts, ranging
from the de novo presentation of small cell prostatic carcinoma to a treatment-emergent …

Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy
of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant …

Tumours adapt to increasingly potent targeted therapies by transitioning to alternative
lineage states. In prostate cancer, the widespread clinical application of androgen receptor …

The median survival of patients with small cell neuroendocrine carcinoma is significantly
shorter than that of patients with classic acinar-type adenocarcinoma. Small cell …

Metabolic reprogramming has been recognised as a hallmark in solid tumours. Malignant
modification of the tumour's bioenergetics provides energy for tumour growth and …

Neuroendocrine differentiation (NED) marks a structural and functional feature of certain
cancers, including prostate cancer (PCa), whereby the malignant tissue contains a …

The correct diagnosis of small cell carcinoma (SCC) of the prostate is critical because of its
aggressive behavior and poor prognosis. The histopathologic diagnosis could be …

BACKGROUND Capsaicin, the active compound in chili peppers, has demonstrated anti‐
carcinogenic properties in vitro in a number of malignancies, including the prostate. In the …